Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

HER2 positivity predicts a benefit from paclitaxel treatment after adjuvant chemotherapy

Nature Clinical Practice Oncology volume 5, pages 252–253 (2008)Cite this article

boxed-textHayes DF et al. (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357: 1496–1506

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Paik S et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24: 3726–3734

    Article  CAS  Google Scholar 

  2. Berry DA et al. (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295: 1658–1667

    Article  CAS  Google Scholar 

  3. Andre F et al. (2007) Estrogen receptor expression and efficacy of docetaxel in early breast cancer: a pooled analysis of 3,490 patients included in two randomized trials [abstract]. J Clin Oncol 25 (Suppl): 537

    Google Scholar 

  4. Henderson IC et al. (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976–983

    Article  CAS  Google Scholar 

  5. Pritchard KI et al. (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354: 2103–2111

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Mandy Aujla, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Tata Memorial Hospital, Dr E Borges Road, Parel, Mumbai 400012, India sudeepgupta@tatahospital.net

Authors and Affiliations

  1. S Gupta is an Associate Professor of Medical Oncology and a Member of the Breast Cancer Working Group at the Tata Memorial Hospital, Mumbai, India.,

    Sudeep Gupta

Authors
  1. Sudeep Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gupta, S. HER2 positivity predicts a benefit from paclitaxel treatment after adjuvant chemotherapy. Nat Rev Clin Oncol 5, 252–253 (2008). https://doi.org/10.1038/ncponc1092

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc1092

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing